Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association of vascular risk factors and cerebrovascular pathology with Alzheimer disease pathologic changes in individuals without Dementia

  • Lorenzini, Luigi
  • Gispert, Juan Domingo
  • Barkhof, Frederik
Background and objectives: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition. Methods: This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal). Results: A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42. Discussion: In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification., EPAD is supported by the EU/EFPIA Innovative Medicines Initiative (IMI) grant agreement 115736. The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors, and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms

  • Stankeviciute, Laura
  • Blackman, Jonathan
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Iranzo, Álex
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
Sleep disturbances are prevalent in Alzheimer's disease (AD), affecting individuals during its early stages. We investigated associations between subjective sleep measures and cerebrospinal fluid (CSF) biomarkers of AD in adults with mild cognitive symptoms from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, considering the influence of memory performance. A total of 442 participants aged >50 years with a Clinical Dementia Rating (CDR) score of 0.5 completed the Pittsburgh Sleep Quality Index questionnaire and underwent neuropsychological assessment, magnetic resonance imaging acquisition, and CSF sampling. We analysed the relationship of sleep quality with CSF AD biomarkers and cognitive performance in separated multivariate linear regression models, adjusting for covariates. Poorer cross-sectional sleep quality was associated with lower CSF levels of phosphorylated tau and total tau alongside better immediate and delayed memory performance. After adjustment for delayed memory scores, associations between CSF biomarkers and sleep quality became non-significant, and further analysis revealed that memory performance mediated this relationship. In post hoc analyses, poorer subjective sleep quality was associated with lesser hippocampal atrophy, with memory performance also mediating this association. In conclusion, worse subjective sleep quality is associated with less altered AD biomarkers in adults with mild cognitive symptoms (CDR score 0.5). These results could be explained by a systematic recall bias affecting subjective sleep assessment in individuals with incipient memory impairment. Caution should therefore be exercised when interpreting subjective sleep quality measures in memory-impaired populations, emphasising the importance of complementing subjective measures with objective assessments., Data used in the preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD-LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: https://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. The EPAD-LCS was launched in 2015 as a public–private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement number 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the amypad-dpms randomized clinical trial

  • Altomare, Daniele
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Amyloid Imaging to Prevent Alzheimer&apos;s Disease (AMYPAD) Consortium
Importance: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. Objective: To assess the clinical effect of amyloid PET in memory clinic patients. Design, setting, and participants: The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics. Participants were allocated (using a minimization method) to 3 study groups based on the performance of amyloid PET: arm 1, early in the diagnostic workup (within 1 month); arm 2, late in the diagnostic workup (after a mean [SD] 8 [2] months); or arm 3, if and when the managing physician chose. Participants were patients with subjective cognitive decline plus (SCD+; SCD plus clinical features increasing the likelihood of preclinical Alzheimer disease), mild cognitive impairment (MCI), or dementia; they were assessed at baseline and after 3 months. Recruitment took place between April 16, 2018, and October 30, 2020. Data analysis was performed from July 2022 to January 2023. Intervention: Amyloid PET. Main outcome and measure: The main outcome was the difference between arm 1 and arm 2 in the proportion of participants receiving an etiological diagnosis with a very high confidence (ie, ≥90% on a 50%-100% visual numeric scale) after 3 months. Results: A total of 844 participants were screened, and 840 were enrolled (291 in arm 1, 271 in arm 2, 278 in arm 3). Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). After 3 months, 109 of 272 participants (40%) in arm 1 had a diagnosis with very high confidence vs 30 of 260 (11%) in arm 2 (P < .001). This was consistent across cognitive stages (SCD+: 25/84 [30%] vs 5/78 [6%]; P < .001; MCI: 45/108 [42%] vs 9/102 [9%]; P < .001; dementia: 39/80 [49%] vs 16/80 [20%]; P < .001). Conclusion and relevance: In this study, early amyloid PET allowed memory clinic patients to receive an etiological diagnosis with very high confidence after only 3 months compared with patients who had not undergone amyloid PET. These findings support the implementation of amyloid PET early in the diagnostic workup of memory clinic patients. Trial registration: EudraCT Number: 2017-002527-21., The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project is funded by the EU European Federation of Pharmaceutical Industries and Associations (EFPIA) Innovative Medicines Initiative 2 Joint Undertaking (IMI 2 JU) (grant agreement 115952). IMI 2 JU aims to advance the development of medicines by facilitating open collaboration on research. To do that, it has funded collaborative research projects that bring together all the parties involved in health research, including universities and pharmaceutical companies. Specifically, the AMYPAD consortium consists of several academic partners and 3 pharmaceutical companies (Life Molecular Imaging, GE Healthcare, and Janssen). Dr Altomare received funding from the Fondation Recherche Alzheimer and Swiss National Science Foundation (project CRSK-3_196354 / 1). Dr Barkhof is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at University College London Hospitals. Dr Berkhof is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health Holland, Top Sector Life Sciences & Health (PPP-allowance; LSHM20106), and received funding from the European Union (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Ms Caprioglio was supported by the EU-EFPIA IMI 2 JU AMYPAD. Dr van Maurik is recipient of the collaboration project ABIDE-clinical utility, which is co-funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships and Life Molecular Imaging (grant LSHM18075). Dr Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), Velux Foundation (project 1123), Schmidheiny Foundation, and Aetas Foundation. Dr Grau-Rivera received funding from the Alzheimer’s Association (2019-AARF-644568) and Instituto de Salud Carlos III (PI19/00117). Dr Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and received funding from the EU-EFPIA IMI 2 JU AMYPAD. Dr Drzezga received funding from AMYPAD, Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), Europäischen Fonds für regionale Entwicklung (EFRE)/Leitmarkt, University of Cologne, and Forschungszentrum Jülich (Novartis clinical trial). Dr Jessen received funding from the BMBF, DFG, H2020, and IMI. Dr Nordberg received funding from AMYPAD, Swedish Foundation for Strategic Research (RB12-01929), Swedish Research Council (2017-06086, 2017-02965, 2020-019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer Foundation, Recherche Sur Alzheimer Fondation, France, and Michael J. Fox Foundation (MJFF-019728). Dr Walker received funding from Health Technology Assessment NIHR, Lewy Body Society, and ARUK. Dr Edison was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). Dr Demonet received funding from the Biogen EMBARK study, Empiris Foundation, Solis Foundation, OM Pharma, and Leenaards Foundation. Dr Frisoni received funding from the EU-EFPIA IMI 2 JU European Prevention of Alzheimer’s Dementia consortium (grant agreement 115736) and AMYPAD; the Swiss National Science Foundation (COSCODE, grant 320030_182772); Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and Velux Foundation. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; and Fondation Chmielewski, Genève. Competitive research projects have been funded by H2020, Human Brain Project, IMI and IMI 2, Swiss National Science Foundation, and Velux Foundation. The Barcelonaβeta Brain Research Center memory center received funding from the Barcelona City Council (agreement 20XC0354) and Biogen.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Eigenvector centrality dynamics are related to Alzheimer’s disease pathological changes in non-demented individuals

  • Lorenzini, Luigi
  • Gispert, Juan Domingo
  • Wink, Alle Meije
Amyloid-β accumulation starts in highly connected brain regions and is associated with functional connectivity alterations in the early stages of Alzheimer's disease. This regional vulnerability is related to the high neuronal activity and strong fluctuations typical of these regions. Recently, dynamic functional connectivity was introduced to investigate changes in functional network organization over time. High dynamic functional connectivity variations indicate increased regional flexibility to participate in multiple subnetworks, promoting functional integration. Currently, only a limited number of studies have explored the temporal dynamics of functional connectivity in the pre-dementia stages of Alzheimer's disease. We study the associations between abnormal cerebrospinal fluid amyloid and both static and dynamic properties of functional hubs, using eigenvector centrality, and their relationship with cognitive performance, in 701 non-demented participants from the European Prevention of Alzheimer's Dementia cohort. Voxel-wise eigenvector centrality was computed for the whole functional magnetic resonance imaging time series (static), and within a sliding window (dynamic). Differences in static eigenvector centrality between amyloid positive (A+) and negative (A-) participants and amyloid-tau groups were found in a general linear model. Dynamic eigenvector centrality standard deviation and range were compared between groups within clusters of significant static eigenvector centrality differences, and within 10 canonical resting-state networks. The effect of the interaction between amyloid status and cognitive performance on dynamic eigenvector centrality variability was also evaluated with linear models. Models were corrected for age, sex, and education level. Lower static centrality was found in A+ participants in posterior brain areas including a parietal and an occipital cluster; higher static centrality was found in a medio-frontal cluster. Lower eigenvector centrality variability (standard deviation) occurred in A+ participants in the frontal cluster. The default mode network and the dorsal visual networks of A+ participants had lower dynamic eigenvector centrality variability. Centrality variability in the default mode network and dorsal visual networks were associated with cognitive performance in the A- and A+ groups, with lower variability being observed in A+ participants with good cognitive scores. Our results support the role and timing of eigenvector centrality alterations in very early stages of Alzheimer's disease and show that centrality variability over time adds relevant information on the dynamic patterns that cause static eigenvector centrality alterations. We propose that dynamic eigenvector centrality is an early biomarker of the interplay between early Alzheimer's disease pathology and cognitive decline., EPAD is supported by the European Union/European federation of pharmaceutical industries and associations (EFPIA) Innovative Medicines Initiative (IMI) grant agreement 115736. A.M.W., L.C., H.M., and F.B. are supported by Amyloid Imaging to Prevent Alzheimer’s disease (AMYPAD—IMI 115952). F.B. is supported by the National Institute for health and care research (NIHR) biomedical research center at University college of London hospital (UCLH). L.C. has received research support from GE Healthcare (paid to institution). H.M. is supported by the Dutch Heart Foundation (2020T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme, provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland. K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JMW is supported by the UK Dementia Research Institute (Foundation Chair) which receives its funding from Dementia research institute (DRI) Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and the Agencia Estatal de Investigación Proyectos de I + D + i RETOS INVESTIGACIÓN (RTI2018-102261-B-I00).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: results of the Barcelona summit

  • Molinuevo, José Luis
  • Camí, Jordi, 1952-
  • Carné, Xavier
  • Carrillo, Maria C.
  • Georges, Jean
  • Isaac, Maria B.
  • Khachaturian, Zaven
  • Kim, Scott Y.H.
  • Morris, John C.
  • Pasquier, Florence
  • Ritchie, Craig
  • Sperling, Reisa
  • Karlawish, Jason
Alzheimer's disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal therapeutic success window. We review the justification for conducting trials in the preclinical stage and highlight novel ethical challenges that arise and are related to determining appropriate risk-benefit ratios and disclosing individuals' biomarker status. We propose that to conduct clinical trials with these participants, we need to improve public understanding of AD using unified vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming these challenges will justify clinical trials in preclinical AD at the societal level and aid to the development of societal and legal support for trial participants., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: data from the European Prevention of Alzheimer's Disease (EPAD) cohort

  • Brugulat Serrat, Anna, 1986-
  • Tsoy, Elena
  • Sánchez Benavides, Gonzalo
  • Milà Alomà, Marta
  • Gaynor, Leslie S.
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Kramer, Joel H.
  • Possin, Katherine L.
  • European Prevention of Alzheimer&apos;s Disease (EPAD) Consortium
INTRODUCTION: Sensitive memory paradigms may allow the detection of subtle memory changes associated with early Alzheimer's pathology in individuals without established clinical symptomatology. METHODS: We explored the cross-sectional association between performance on Tablet-based Cognitive Assessment Tool (TabCAT) Favorites, a brief computerized memory test, with cerebrospinal fluid AT status (A for amyloid-ß and T for phosphorylated tau) and its discriminative validity in 727 clinically asymptomatic participants from the European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study. Episodic memory was also evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-MI). RESULTS: Compared to A-T- individuals, poorer TabCAT Favorites Total Correct (Favorites-TC) cross-sectional performance was associated with an increased likelihood of A+T+ status, but not A+T- status. There were no significant associations between AT status and RBANS-MI. Among individuals with low Favorites-TC performance, AT status predicted progression on the Clinical Dementia Rating > 0. DISCUSSION: Favorites-TC is a sensitive measure for the early detection of cognitive changes in the early stages of the AD continuum. Highlights: We explored Tablet-based Cognitive Assessment Tool (TabCAT) Favorites scores and cerebrospinal fluid (CSF) AT status (A for amyloid-ß and T for phosphorylated tau) in asymptomatic individuals. Poorer Favorites performance linked to higher A+T+ likelihood. TabCAT Favorites is a sensitive tool for detecting early cognitive changes in Alzheimer's disease (AD)., The authors express their most sincere gratitude to the EPAD LCS participants. This work used data and/or samples from the EPAD project, which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer's Association Grant [SG-21-818099-EPAD]. AB-S receives funding from Alzheimer's Association Clinician Scientist Fellowship Program (AACSF-23-1145154). ET received funding from the NIH (R21AG080410, R35AG072362, U01NS128913, P30AG062422, R01AG059183, and UG3AG090679) and Global Brain Health Institute. GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. MM-A receives funding from Alzheimer's Association Research Fellowship Program (AARF-23-1141384). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). JDG DG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). KP receives funding from the NIH (U01NS128913, UH3NS105557, and R35AG072362), Quest Diagnostics, the Global Brain Health Institute, the Merck Foundation, and the Rainwater Charitable Foundation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Subclinical atherosclerosis and brain metabolism in middle-aged individuals: The PESA study

  • Cortes-Canteli, Marta
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Toribio Fernández, Raquel
  • Tristão Pereira, Catarina
  • Falcón, Carles
  • Oliva, Belén
  • Mendiguren, José
  • Fernández Friera, Letícia
  • Sanz, Javier
  • García-Ruiz de Morales, José María
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Ibáñez, Borja
  • Molinuevo, José Luis
  • Fuster, Valentín
Background: Atherosclerosis has been linked to cognitive decline in late life; however, the impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain metabolism at earlier stages remains unexplored. Objectives: This study sought to determine the association between brain metabolism, subclinical atherosclerosis, and CVRFs in middle-aged asymptomatic individuals. Methods: This study included 547 asymptomatic middle-aged participants (50 ± 4 years, 82% men) from the PESA (Progression of Early Subclinical Atherosclerosis) study with evidence of subclinical atherosclerosis. Participants underwent 18F-fluorodeoxyglucose (FDG)-positron emission tomography. Global brain FDG uptake and voxel-wise analyses were used to evaluate the associations of cerebral metabolism with CVRFs and atherosclerotic plaque burden in carotids and femorals assessed by 3-dimensional vascular ultrasound. Results: Global FDG uptake showed an inverse correlation with 30-year Framingham Risk Score (FRS) (β = -0.15, p < 0.001). This association was mainly driven by the presence of hypertension (d = 0.36, p < 0.001). Carotid plaque burden was inversely associated with global brain FDG uptake (β = -0.16, p < 0.001), even after adjusting for 30-year FRS. Voxel-wise approaches revealed that the brain areas most strongly affected by hypometabolism in association with 30-year FRS, hypertension, and carotid plaque burden were parietotemporal regions (angular, supramarginal, and inferior/middle temporal gyri) and the cingulate gyrus. Conclusions: In asymptomatic middle-aged individuals, cardiovascular risk is associated with brain hypometabolism, with hypertension being the modifiable CVRF showing the strongest association. Subclinical carotid plaque burden is also linked to reduced brain metabolism independently of CVRFs. Cerebral areas showing hypometabolism include those known to be affected in dementia. These data reinforce the need to control CVRFs early in life in order to potentially reduce the brain's midlife vulnerability to future cognitive dysfunction., The study also receives funding from the Instituto de Salud Carlos III, Madrid, Spain (ISCIII, PI15/02019), the European Regional Development Fund (ERDF–A Way to Build Europe) and the European Social Fund (ESF–Investing in Your Future). Dr. Cortes-Canteli was supported by a Miguel Servet type I research contract (ISCIII, CP16/00174 & MS16/00174) and the Fondo de Investigación Sanitaria (ISCIII, PI17/00590 & PI20/00819). Dr. Toribio-Fernandez was supported by the Iniciativa de Empleo Juvenil of the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (PEJD-2018-POST/BMD-9259). Ms. Tristão-Pereira was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). Dr. Gispert is supported by the Ministerio de Ciencia e Innovación (MCIN; RYC-2013-13054) and Dr. B. Ibanez by the European Research Council (ERC-2018-CoG 819775-MATRIX). The CNIC is supported by the ISCIII, the MCIN, and the Pro-CNIC Foundation. The BBRC is mainly funded by the “la Caixa” Foundation (ID 100010434) under agreement LCF/PR/GN17/50300004, the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD under grant agreement 115736, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115952. This Joint Undertaking receives support from the European Union Horizon 2020 Research and Innovation Programme and the EFPIA. Dr. Molinuevo has served as a consultant for, sat on advisory boards of, or delivered lectures in symposia sponsored by Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. Dr. Gispert has given lectures in symposia sponsored by General Electric, Philips, and Biogen. Dr. Sanchez-Gonzalez is a Philips employee. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study

  • Altomare, Daniele
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Frisoni, Giovanni B.
  • AMYPAD Consortium
Data de publicació electrónica: 17-06-2022, Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. Methods: participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion: the features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results., This communication reflects the views of the authors and neither the Innovative Medicines Initiative (IMI) nor the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are liable for any use that may be made of the information contained herein. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève. Competitive research projects have been funded by: H2020, Human Brain Project, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation. External sites affiliated with CHUT: Françoise Desclaux (Geriatrics department of Lavaur), Marie-Noelle Cufi (Geriatrics department of Lavaur), and Jérémie Pariente (department of Neurology of Toulouse University Hospital, Inserm Toulouse NeuroImaging Center, Université Paul Sabatier, Centre d'Investigation Clinique de Toulouse CIC 1436). The BBRC's memory center received funding from the Barcelona City Council (agreement # 20XC0354) and Biogen. Daniele Altomare received funding from the Fondation Recherche Alzheimer and the Swiss National Science Foundation (project CRSK-3_196354/1). Camilla Caprioglio was supported by EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Johannes Berkhof is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106), and received funding from the EU (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Valentina Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), by the Velux Foundation (project 1123), by the Schmidheiny foundation, and by the Aetas foundation. Oriol Grau-Rivera received funding from Alzheimer's Association (2019-AARF-644568) and Instituto de Salud Carlos III (PI19/00117). Juan Domingo Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Alexander Drzezga received funding by Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), DFG (Deutsche Forschungsgemeinschaft), BMBF (Bundesministerium für Bildung und Forschung), EFRE/Leitmarkt (Europäischen Fonds für regionale Entwicklung), University of Cologne, Forschungszentrum Jülich. Novartis clinical trial. Claus Escher received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Frank Jessen received funding from BMBF, DFG, H2020, and IMI. Agneta Nordberg received funding from Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), Swedish Foundation for Strategic Research (RB12-01929), Swedish Research Council (2017-06086, 2017-02965, 2020-019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer foundation, Recherche Sur Alzheimer Fondation, France, and Michael J Fox Foundation (MJFF-019728). Zuzana Walker received funding from HTA-NIHR, Lewy body Society, and ARUK. Jean-François Demonet received funding from Biogen “EMBARK” study, Empiris foundation, Solis foundation, OM Pharma, and Leenaards foundation. Frederik Barkhof is supported by the NIHR Biomedical Research Centre at University College London Hospitals. Giovanni B. Frisoni received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation (COSCODE, grant number: 320030_182772); A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and VELUX Foundation. Open access funding provided by Universite de Geneve.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants

  • Brugulat Serrat, Anna, 1986-
  • Salvadó, Glòria
  • Operto, Grégory
  • Cacciaglia, Raffaele
  • Sudre, Carole H.
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Gramunt Fombuena, Nina
  • Minguillón, Carolina
  • Fauria, Karine
  • Barkhof, Frederik
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • ALFA Study
White matter hyperintensities (WMH) have been extensively associated with cognitive impairment and reductions in gray matter volume (GMv) independently. This study explored whether WMH lesion volume mediates the relationship between cerebral patterns of GMv and cognition in 521 (mean age 57.7 years) cognitively unimpaired middle-aged individuals. Episodic memory (EM) was measured with the Memory Binding Test and executive functions (EF) using five WAIS-IV subtests. WMH were automatically determined from T2 and FLAIR sequences and characterized using diffusion-weighted imaging (DWI) parameters. WMH volume was entered as a mediator in a voxel-wise mediation analysis relating GMv and cognitive performance (with both EM and EF composites and the individual tests independently). The mediation model was corrected by age, sex, education, number of Apolipoprotein E (APOE)-ε4 alleles and total intracranial volume. We found that even at very low levels of WMH burden in the cohort (median volume of 3.2 mL), higher WMH lesion volume was significantly associated with a widespread pattern of lower GMv in temporal, frontal, and cerebellar areas. WMH mediated the relationship between GMv and EF, mainly driven by processing speed, but not EM. DWI parameters in these lesions were compatible with incipient demyelination and axonal loss. These findings lead to the reflection on the relevance of the control of cardiovascular risk factors in middle-aged individuals as a valuable preventive strategy to reduce or delay cognitive decline., Research conducted by José Luis Molinuevo receives support from: the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD grant agreement #115952; the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement #115736 and the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AETIONOMY grant #115568. He is/has been a scientific consultant and/or attended scientific advisory boards of Alergan, Roche diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, Raman Health. Research conducted by Frederik Barkhof receives support from AMYPAD (IMI); EuroPOND (H2020); UK MS Society; Dutch MS Society; PICTURE (IMDI-NWO); NIHR UCLH; Biomedical Research Centre (BRC) and ECTRIMS-MAGNIMS. He has received consultancy fees from Bayer Pharma, Biogen-IDEC, TEVA, Merck, Novartis, Roche, Jansen Research, Genzyme-Sanofi, IXICO Ltd, GeNeuro and Apitope Ltd.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Eigenvector centrality dynamics are related to Alzheimer’s disease pathological changes in non-demented individuals

  • Lorenzini, Luigi
  • Gispert, Juan Domingo
  • Wink, Alle Meije
Amyloid-β accumulation starts in highly connected brain regions and is associated with functional connectivity alterations in the early stages of Alzheimer's disease. This regional vulnerability is related to the high neuronal activity and strong fluctuations typical of these regions. Recently, dynamic functional connectivity was introduced to investigate changes in functional network organization over time. High dynamic functional connectivity variations indicate increased regional flexibility to participate in multiple subnetworks, promoting functional integration. Currently, only a limited number of studies have explored the temporal dynamics of functional connectivity in the pre-dementia stages of Alzheimer's disease. We study the associations between abnormal cerebrospinal fluid amyloid and both static and dynamic properties of functional hubs, using eigenvector centrality, and their relationship with cognitive performance, in 701 non-demented participants from the European Prevention of Alzheimer's Dementia cohort. Voxel-wise eigenvector centrality was computed for the whole functional magnetic resonance imaging time series (static), and within a sliding window (dynamic). Differences in static eigenvector centrality between amyloid positive (A+) and negative (A-) participants and amyloid-tau groups were found in a general linear model. Dynamic eigenvector centrality standard deviation and range were compared between groups within clusters of significant static eigenvector centrality differences, and within 10 canonical resting-state networks. The effect of the interaction between amyloid status and cognitive performance on dynamic eigenvector centrality variability was also evaluated with linear models. Models were corrected for age, sex, and education level. Lower static centrality was found in A+ participants in posterior brain areas including a parietal and an occipital cluster; higher static centrality was found in a medio-frontal cluster. Lower eigenvector centrality variability (standard deviation) occurred in A+ participants in the frontal cluster. The default mode network and the dorsal visual networks of A+ participants had lower dynamic eigenvector centrality variability. Centrality variability in the default mode network and dorsal visual networks were associated with cognitive performance in the A- and A+ groups, with lower variability being observed in A+ participants with good cognitive scores. Our results support the role and timing of eigenvector centrality alterations in very early stages of Alzheimer's disease and show that centrality variability over time adds relevant information on the dynamic patterns that cause static eigenvector centrality alterations. We propose that dynamic eigenvector centrality is an early biomarker of the interplay between early Alzheimer's disease pathology and cognitive decline., EPAD is supported by the European Union/European federation of pharmaceutical industries and associations (EFPIA) Innovative Medicines Initiative (IMI) grant agreement 115736. A.M.W., L.C., H.M., and F.B. are supported by Amyloid Imaging to Prevent Alzheimer’s disease (AMYPAD—IMI 115952). F.B. is supported by the National Institute for health and care research (NIHR) biomedical research center at University college of London hospital (UCLH). L.C. has received research support from GE Healthcare (paid to institution). H.M. is supported by the Dutch Heart Foundation (2020T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme, provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland. K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JMW is supported by the UK Dementia Research Institute (Foundation Chair) which receives its funding from Dementia research institute (DRI) Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and the Agencia Estatal de Investigación Proyectos de I + D + i RETOS INVESTIGACIÓN (RTI2018-102261-B-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study

  • Altomare, Daniele
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Frisoni, Giovanni B.
  • AMYPAD Consortium
Data de publicació electrónica: 17-06-2022, Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. Methods: participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion: the features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results., This communication reflects the views of the authors and neither the Innovative Medicines Initiative (IMI) nor the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are liable for any use that may be made of the information contained herein. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève. Competitive research projects have been funded by: H2020, Human Brain Project, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation. External sites affiliated with CHUT: Françoise Desclaux (Geriatrics department of Lavaur), Marie-Noelle Cufi (Geriatrics department of Lavaur), and Jérémie Pariente (department of Neurology of Toulouse University Hospital, Inserm Toulouse NeuroImaging Center, Université Paul Sabatier, Centre d'Investigation Clinique de Toulouse CIC 1436). The BBRC's memory center received funding from the Barcelona City Council (agreement # 20XC0354) and Biogen. Daniele Altomare received funding from the Fondation Recherche Alzheimer and the Swiss National Science Foundation (project CRSK-3_196354/1). Camilla Caprioglio was supported by EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Johannes Berkhof is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106), and received funding from the EU (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Valentina Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), by the Velux Foundation (project 1123), by the Schmidheiny foundation, and by the Aetas foundation. Oriol Grau-Rivera received funding from Alzheimer's Association (2019-AARF-644568) and Instituto de Salud Carlos III (PI19/00117). Juan Domingo Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Alexander Drzezga received funding by Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), DFG (Deutsche Forschungsgemeinschaft), BMBF (Bundesministerium für Bildung und Forschung), EFRE/Leitmarkt (Europäischen Fonds für regionale Entwicklung), University of Cologne, Forschungszentrum Jülich. Novartis clinical trial. Claus Escher received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Frank Jessen received funding from BMBF, DFG, H2020, and IMI. Agneta Nordberg received funding from Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), Swedish Foundation for Strategic Research (RB12-01929), Swedish Research Council (2017-06086, 2017-02965, 2020-019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer foundation, Recherche Sur Alzheimer Fondation, France, and Michael J Fox Foundation (MJFF-019728). Zuzana Walker received funding from HTA-NIHR, Lewy body Society, and ARUK. Jean-François Demonet received funding from Biogen “EMBARK” study, Empiris foundation, Solis foundation, OM Pharma, and Leenaards foundation. Frederik Barkhof is supported by the NIHR Biomedical Research Centre at University College London Hospitals. Giovanni B. Frisoni received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation (COSCODE, grant number: 320030_182772); A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and VELUX Foundation. Open access funding provided by Universite de Geneve.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: data from the European Prevention of Alzheimer's Disease (EPAD) cohort

  • Brugulat Serrat, Anna, 1986-
  • Tsoy, Elena
  • Sánchez Benavides, Gonzalo
  • Milà Alomà, Marta
  • Gaynor, Leslie S.
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Kramer, Joel H.
  • Possin, Katherine L.
  • European Prevention of Alzheimer&apos;s Disease (EPAD) Consortium
INTRODUCTION: Sensitive memory paradigms may allow the detection of subtle memory changes associated with early Alzheimer's pathology in individuals without established clinical symptomatology. METHODS: We explored the cross-sectional association between performance on Tablet-based Cognitive Assessment Tool (TabCAT) Favorites, a brief computerized memory test, with cerebrospinal fluid AT status (A for amyloid-ß and T for phosphorylated tau) and its discriminative validity in 727 clinically asymptomatic participants from the European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study. Episodic memory was also evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-MI). RESULTS: Compared to A-T- individuals, poorer TabCAT Favorites Total Correct (Favorites-TC) cross-sectional performance was associated with an increased likelihood of A+T+ status, but not A+T- status. There were no significant associations between AT status and RBANS-MI. Among individuals with low Favorites-TC performance, AT status predicted progression on the Clinical Dementia Rating > 0. DISCUSSION: Favorites-TC is a sensitive measure for the early detection of cognitive changes in the early stages of the AD continuum. Highlights: We explored Tablet-based Cognitive Assessment Tool (TabCAT) Favorites scores and cerebrospinal fluid (CSF) AT status (A for amyloid-ß and T for phosphorylated tau) in asymptomatic individuals. Poorer Favorites performance linked to higher A+T+ likelihood. TabCAT Favorites is a sensitive tool for detecting early cognitive changes in Alzheimer's disease (AD)., The authors express their most sincere gratitude to the EPAD LCS participants. This work used data and/or samples from the EPAD project, which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer's Association Grant [SG-21-818099-EPAD]. AB-S receives funding from Alzheimer's Association Clinician Scientist Fellowship Program (AACSF-23-1145154). ET received funding from the NIH (R21AG080410, R35AG072362, U01NS128913, P30AG062422, R01AG059183, and UG3AG090679) and Global Brain Health Institute. GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. MM-A receives funding from Alzheimer's Association Research Fellowship Program (AARF-23-1141384). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). JDG DG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). KP receives funding from the NIH (U01NS128913, UH3NS105557, and R35AG072362), Quest Diagnostics, the Global Brain Health Institute, the Merck Foundation, and the Rainwater Charitable Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms

  • Stankeviciute, Laura
  • Blackman, Jonathan
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Iranzo, Álex
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
Sleep disturbances are prevalent in Alzheimer's disease (AD), affecting individuals during its early stages. We investigated associations between subjective sleep measures and cerebrospinal fluid (CSF) biomarkers of AD in adults with mild cognitive symptoms from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, considering the influence of memory performance. A total of 442 participants aged >50 years with a Clinical Dementia Rating (CDR) score of 0.5 completed the Pittsburgh Sleep Quality Index questionnaire and underwent neuropsychological assessment, magnetic resonance imaging acquisition, and CSF sampling. We analysed the relationship of sleep quality with CSF AD biomarkers and cognitive performance in separated multivariate linear regression models, adjusting for covariates. Poorer cross-sectional sleep quality was associated with lower CSF levels of phosphorylated tau and total tau alongside better immediate and delayed memory performance. After adjustment for delayed memory scores, associations between CSF biomarkers and sleep quality became non-significant, and further analysis revealed that memory performance mediated this relationship. In post hoc analyses, poorer subjective sleep quality was associated with lesser hippocampal atrophy, with memory performance also mediating this association. In conclusion, worse subjective sleep quality is associated with less altered AD biomarkers in adults with mild cognitive symptoms (CDR score 0.5). These results could be explained by a systematic recall bias affecting subjective sleep assessment in individuals with incipient memory impairment. Caution should therefore be exercised when interpreting subjective sleep quality measures in memory-impaired populations, emphasising the importance of complementing subjective measures with objective assessments., Data used in the preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD-LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: https://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. The EPAD-LCS was launched in 2015 as a public–private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement number 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of vascular risk factors and cerebrovascular pathology with Alzheimer disease pathologic changes in individuals without Dementia

  • Lorenzini, Luigi
  • Gispert, Juan Domingo
  • Barkhof, Frederik
Background and objectives: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ1-42) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau181), atrophy, and cognition. Methods: This retrospective study included nondemented participants (Clinical Dementia Rating < 1) from the European Prevention of Alzheimer's Dementia (EPAD) cohort and assessed VRFs with the Framingham risk score (FRS) and cSVD features on MRI using visual scales and white matter hyperintensity volumes. After preliminary linear analysis, we used structural equation modeling (SEM) to create a "cSVD severity" latent variable and assess the direct and indirect effects of FRS and cSVD severity on Aβ1-42, P-tau181, gray matter volume (baseline and longitudinal), and cognitive performance (baseline and longitudinal). Results: A total cohort of 1,592 participants were evaluated (mean age = 65.5 ± 7.4 years; 56.16% F). We observed positive associations between FRS and all cSVD features (all p < 0.05) and a negative association between FRS and Aβ1-42 (β = -0.04 ± 0.01). All cSVD features were negatively associated with CSF Aβ1-42 (all p < 0.05). Using SEM, the cSVD severity fully mediated the association between FRS and CSF Aβ1-42 (indirect effect: β = -0.03 ± 0.01), also when omitting vascular amyloid-related markers. We observed a significant indirect effect of cSVD severity on P-tau181 (indirect effect: β = 0.12 ± 0.03), baseline and longitudinal gray matter volume (indirect effect: β = -0.10 ± 0.03; β = -0.12 ± 0.05), and baseline cognitive performance (indirect effect: β = -0.16 ± 0.03) through CSF Aβ1-42. Discussion: In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ1-42 and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification., EPAD is supported by the EU/EFPIA Innovative Medicines Initiative (IMI) grant agreement 115736. The project leading to this paper has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors, and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants

  • Brugulat Serrat, Anna, 1986-
  • Salvadó, Glòria
  • Operto, Grégory
  • Cacciaglia, Raffaele
  • Sudre, Carole H.
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Gramunt Fombuena, Nina
  • Minguillón, Carolina
  • Fauria, Karine
  • Barkhof, Frederik
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • ALFA Study
White matter hyperintensities (WMH) have been extensively associated with cognitive impairment and reductions in gray matter volume (GMv) independently. This study explored whether WMH lesion volume mediates the relationship between cerebral patterns of GMv and cognition in 521 (mean age 57.7 years) cognitively unimpaired middle-aged individuals. Episodic memory (EM) was measured with the Memory Binding Test and executive functions (EF) using five WAIS-IV subtests. WMH were automatically determined from T2 and FLAIR sequences and characterized using diffusion-weighted imaging (DWI) parameters. WMH volume was entered as a mediator in a voxel-wise mediation analysis relating GMv and cognitive performance (with both EM and EF composites and the individual tests independently). The mediation model was corrected by age, sex, education, number of Apolipoprotein E (APOE)-ε4 alleles and total intracranial volume. We found that even at very low levels of WMH burden in the cohort (median volume of 3.2 mL), higher WMH lesion volume was significantly associated with a widespread pattern of lower GMv in temporal, frontal, and cerebellar areas. WMH mediated the relationship between GMv and EF, mainly driven by processing speed, but not EM. DWI parameters in these lesions were compatible with incipient demyelination and axonal loss. These findings lead to the reflection on the relevance of the control of cardiovascular risk factors in middle-aged individuals as a valuable preventive strategy to reduce or delay cognitive decline., Research conducted by José Luis Molinuevo receives support from: the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD grant agreement #115952; the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement #115736 and the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AETIONOMY grant #115568. He is/has been a scientific consultant and/or attended scientific advisory boards of Alergan, Roche diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, Raman Health. Research conducted by Frederik Barkhof receives support from AMYPAD (IMI); EuroPOND (H2020); UK MS Society; Dutch MS Society; PICTURE (IMDI-NWO); NIHR UCLH; Biomedical Research Centre (BRC) and ECTRIMS-MAGNIMS. He has received consultancy fees from Bayer Pharma, Biogen-IDEC, TEVA, Merck, Novartis, Roche, Jansen Research, Genzyme-Sanofi, IXICO Ltd, GeNeuro and Apitope Ltd.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the amypad-dpms randomized clinical trial

  • Altomare, Daniele
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Amyloid Imaging to Prevent Alzheimer&apos;s Disease (AMYPAD) Consortium
Importance: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. Objective: To assess the clinical effect of amyloid PET in memory clinic patients. Design, setting, and participants: The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics. Participants were allocated (using a minimization method) to 3 study groups based on the performance of amyloid PET: arm 1, early in the diagnostic workup (within 1 month); arm 2, late in the diagnostic workup (after a mean [SD] 8 [2] months); or arm 3, if and when the managing physician chose. Participants were patients with subjective cognitive decline plus (SCD+; SCD plus clinical features increasing the likelihood of preclinical Alzheimer disease), mild cognitive impairment (MCI), or dementia; they were assessed at baseline and after 3 months. Recruitment took place between April 16, 2018, and October 30, 2020. Data analysis was performed from July 2022 to January 2023. Intervention: Amyloid PET. Main outcome and measure: The main outcome was the difference between arm 1 and arm 2 in the proportion of participants receiving an etiological diagnosis with a very high confidence (ie, ≥90% on a 50%-100% visual numeric scale) after 3 months. Results: A total of 844 participants were screened, and 840 were enrolled (291 in arm 1, 271 in arm 2, 278 in arm 3). Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). After 3 months, 109 of 272 participants (40%) in arm 1 had a diagnosis with very high confidence vs 30 of 260 (11%) in arm 2 (P < .001). This was consistent across cognitive stages (SCD+: 25/84 [30%] vs 5/78 [6%]; P < .001; MCI: 45/108 [42%] vs 9/102 [9%]; P < .001; dementia: 39/80 [49%] vs 16/80 [20%]; P < .001). Conclusion and relevance: In this study, early amyloid PET allowed memory clinic patients to receive an etiological diagnosis with very high confidence after only 3 months compared with patients who had not undergone amyloid PET. These findings support the implementation of amyloid PET early in the diagnostic workup of memory clinic patients. Trial registration: EudraCT Number: 2017-002527-21., The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project is funded by the EU European Federation of Pharmaceutical Industries and Associations (EFPIA) Innovative Medicines Initiative 2 Joint Undertaking (IMI 2 JU) (grant agreement 115952). IMI 2 JU aims to advance the development of medicines by facilitating open collaboration on research. To do that, it has funded collaborative research projects that bring together all the parties involved in health research, including universities and pharmaceutical companies. Specifically, the AMYPAD consortium consists of several academic partners and 3 pharmaceutical companies (Life Molecular Imaging, GE Healthcare, and Janssen). Dr Altomare received funding from the Fondation Recherche Alzheimer and Swiss National Science Foundation (project CRSK-3_196354 / 1). Dr Barkhof is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at University College London Hospitals. Dr Berkhof is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health Holland, Top Sector Life Sciences & Health (PPP-allowance; LSHM20106), and received funding from the European Union (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Ms Caprioglio was supported by the EU-EFPIA IMI 2 JU AMYPAD. Dr van Maurik is recipient of the collaboration project ABIDE-clinical utility, which is co-funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships and Life Molecular Imaging (grant LSHM18075). Dr Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), Velux Foundation (project 1123), Schmidheiny Foundation, and Aetas Foundation. Dr Grau-Rivera received funding from the Alzheimer’s Association (2019-AARF-644568) and Instituto de Salud Carlos III (PI19/00117). Dr Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and received funding from the EU-EFPIA IMI 2 JU AMYPAD. Dr Drzezga received funding from AMYPAD, Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), Europäischen Fonds für regionale Entwicklung (EFRE)/Leitmarkt, University of Cologne, and Forschungszentrum Jülich (Novartis clinical trial). Dr Jessen received funding from the BMBF, DFG, H2020, and IMI. Dr Nordberg received funding from AMYPAD, Swedish Foundation for Strategic Research (RB12-01929), Swedish Research Council (2017-06086, 2017-02965, 2020-019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer Foundation, Recherche Sur Alzheimer Fondation, France, and Michael J. Fox Foundation (MJFF-019728). Dr Walker received funding from Health Technology Assessment NIHR, Lewy Body Society, and ARUK. Dr Edison was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). Dr Demonet received funding from the Biogen EMBARK study, Empiris Foundation, Solis Foundation, OM Pharma, and Leenaards Foundation. Dr Frisoni received funding from the EU-EFPIA IMI 2 JU European Prevention of Alzheimer’s Dementia consortium (grant agreement 115736) and AMYPAD; the Swiss National Science Foundation (COSCODE, grant 320030_182772); Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and Velux Foundation. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: Association Suisse pour la Recherche sur la Maladie d’Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; and Fondation Chmielewski, Genève. Competitive research projects have been funded by H2020, Human Brain Project, IMI and IMI 2, Swiss National Science Foundation, and Velux Foundation. The Barcelonaβeta Brain Research Center memory center received funding from the Barcelona City Council (agreement 20XC0354) and Biogen.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes

  • Tranfa, Mario
  • Vilor Tejedor, Natàlia, 1988-
  • Gispert, Juan Domingo
  • Lorenzini, Luigi
Background: The accumulation of amyloid-β1-42 (Aβ1-42) peptides and phosphorylated-Tau181 (p-Tau181) tangles from the preclinical stages of Alzheimer's disease (AD) has led to a biological definition of the disease. However, among Aβ1-42-positive individuals, cognitive decline onset varies, and some never develop symptoms. Genetic influences on molecular pathways and their interactions with proteinopathy may underlie this heterogeneity. Leveraging data from a large sample of cognitively intact older adults in the European Prevention of Alzheimer Dementia (EPAD) cohort, we examined how AD-related pathophysiological changes (i.e., Aβ1-42 and p-Tau181), polygenic pathways and their interaction are associated with WM micro- and macrostructural properties. Methods: We selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ1-42 and p-Tau181 measurements available, full genotyping, and structural and diffusion MRI. Polygenic risk scores (PRSs) were computed using 85 AD-related genetic variants. These were mapped to their corresponding genes and, after excluding those belonging to the APOE locus, clustered by function into six pathway-specific PRSs (i.e., immune activation, signal transduction, inflammation, lipid, amyloid, and clearance pathways). Diffusion MRIs were processed through the fixel-based analysis framework to derive fiber density (FD) and fiber cross-section (FC) metrics, which were averaged within WM tracts. Linear models assessed the effects of AD-related pathophysiological changes, global and pathway-specific PRSs, and their interactions on FD and FC at both the tract and fixel levels. Models were corrected for multiple comparisons. Results: P-Tau181 was primarily associated with greater FD. The lipid pathway was associated with greater FD and FC, with these effects predominantly occurring in the left hemisphere, consistent with evidence of hemispheric dominance. The clearance pathway moderated the effect of Aβ1-42 on FD, with a positive slope in A + compared to A- individuals. The immune activation pathway moderated the effect of p-Tau181 on FD, with a negative slope in T + compared to T- individuals. Conclusions: Pathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways., This work was funded by EU/EFPIA Innovative Medicines Initiative (IMI) grant 115736; Horizon 2020 grant 115952. ESL has received support for data curation and storage from the Alzheimer’s Disease Data Initiative (ADDI; paid to institution). LEC’s salary is supported by a MSCA postdoctoral fellowship research grant (101108819) and the Alzheimer Association Research Fellowship (grant 23AARF-1029663). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency grant RYC2022-038136-I, cofunded by the European Union FSE+, and grant PID2022-143106OA-I00 cofunded by the European Union FEDER; NV-T is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, and grant 23S06083-001 funded by the Ajuntament de Barcelona and "la Caixa" Foundation. AA was supported by the Early Detection of Alzheimer's Disease Subtypes (E-DADS) project, an EU Joint Programme—Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). JMW is supported by the UK Dementia Research Institute (funded by the MRC, Alzheimer's Society and Alzheimer's Research UK), the British Heart Foundation, The Fondation Leducq Network on Perivascular Spaces and the Row Fogo Centre for Research into Small Vessel Diseases. HJMMM is supported by the Dutch Heart Foundation (03-004-2020-T049), by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106). LL receives funding from the MSCA postdoctoral fellowship (#101204296).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Subclinical atherosclerosis and brain metabolism in middle-aged individuals: The PESA study

  • Cortes-Canteli, Marta
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Toribio Fernández, Raquel
  • Tristão Pereira, Catarina
  • Falcón, Carles
  • Oliva, Belén
  • Mendiguren, José
  • Fernández Friera, Letícia
  • Sanz, Javier
  • García-Ruiz de Morales, José María
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Ibáñez, Borja
  • Molinuevo, José Luis
  • Fuster, Valentín
Background: Atherosclerosis has been linked to cognitive decline in late life; however, the impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain metabolism at earlier stages remains unexplored. Objectives: This study sought to determine the association between brain metabolism, subclinical atherosclerosis, and CVRFs in middle-aged asymptomatic individuals. Methods: This study included 547 asymptomatic middle-aged participants (50 ± 4 years, 82% men) from the PESA (Progression of Early Subclinical Atherosclerosis) study with evidence of subclinical atherosclerosis. Participants underwent 18F-fluorodeoxyglucose (FDG)-positron emission tomography. Global brain FDG uptake and voxel-wise analyses were used to evaluate the associations of cerebral metabolism with CVRFs and atherosclerotic plaque burden in carotids and femorals assessed by 3-dimensional vascular ultrasound. Results: Global FDG uptake showed an inverse correlation with 30-year Framingham Risk Score (FRS) (β = -0.15, p < 0.001). This association was mainly driven by the presence of hypertension (d = 0.36, p < 0.001). Carotid plaque burden was inversely associated with global brain FDG uptake (β = -0.16, p < 0.001), even after adjusting for 30-year FRS. Voxel-wise approaches revealed that the brain areas most strongly affected by hypometabolism in association with 30-year FRS, hypertension, and carotid plaque burden were parietotemporal regions (angular, supramarginal, and inferior/middle temporal gyri) and the cingulate gyrus. Conclusions: In asymptomatic middle-aged individuals, cardiovascular risk is associated with brain hypometabolism, with hypertension being the modifiable CVRF showing the strongest association. Subclinical carotid plaque burden is also linked to reduced brain metabolism independently of CVRFs. Cerebral areas showing hypometabolism include those known to be affected in dementia. These data reinforce the need to control CVRFs early in life in order to potentially reduce the brain's midlife vulnerability to future cognitive dysfunction., The study also receives funding from the Instituto de Salud Carlos III, Madrid, Spain (ISCIII, PI15/02019), the European Regional Development Fund (ERDF–A Way to Build Europe) and the European Social Fund (ESF–Investing in Your Future). Dr. Cortes-Canteli was supported by a Miguel Servet type I research contract (ISCIII, CP16/00174 & MS16/00174) and the Fondo de Investigación Sanitaria (ISCIII, PI17/00590 & PI20/00819). Dr. Toribio-Fernandez was supported by the Iniciativa de Empleo Juvenil of the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (PEJD-2018-POST/BMD-9259). Ms. Tristão-Pereira was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). Dr. Gispert is supported by the Ministerio de Ciencia e Innovación (MCIN; RYC-2013-13054) and Dr. B. Ibanez by the European Research Council (ERC-2018-CoG 819775-MATRIX). The CNIC is supported by the ISCIII, the MCIN, and the Pro-CNIC Foundation. The BBRC is mainly funded by the “la Caixa” Foundation (ID 100010434) under agreement LCF/PR/GN17/50300004, the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD under grant agreement 115736, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115952. This Joint Undertaking receives support from the European Union Horizon 2020 Research and Innovation Programme and the EFPIA. Dr. Molinuevo has served as a consultant for, sat on advisory boards of, or delivered lectures in symposia sponsored by Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. Dr. Gispert has given lectures in symposia sponsored by General Electric, Philips, and Biogen. Dr. Sanchez-Gonzalez is a Philips employee. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: results of the Barcelona summit

  • Molinuevo, José Luis
  • Camí, Jordi, 1952-
  • Carné, Xavier
  • Carrillo, Maria C.
  • Georges, Jean
  • Isaac, Maria B.
  • Khachaturian, Zaven
  • Kim, Scott Y.H.
  • Morris, John C.
  • Pasquier, Florence
  • Ritchie, Craig
  • Sperling, Reisa
  • Karlawish, Jason
Alzheimer's disease (AD) is among the most significant health care burdens. Disappointing results from clinical trials in late-stage AD persons combined with hopeful results from trials in persons with early-stage suggest that research in the preclinical stage of AD is necessary to define an optimal therapeutic success window. We review the justification for conducting trials in the preclinical stage and highlight novel ethical challenges that arise and are related to determining appropriate risk-benefit ratios and disclosing individuals' biomarker status. We propose that to conduct clinical trials with these participants, we need to improve public understanding of AD using unified vocabulary, resolve the acceptable risk-benefit ratio in asymptomatic participants, and disclose or not biomarker status with attention to study type (observational studies vs clinical trials). Overcoming these challenges will justify clinical trials in preclinical AD at the societal level and aid to the development of societal and legal support for trial participants., The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution.